Raymond James on Taysha Gene Therapies (TSHA): 'Continued Regulatory Progress For TSHA-102; Remain Strong Buy Rated'
Tweet Send to a Friend
Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $13.00 price target on Taysha Gene Therapies (NASDAQ: TSHA)The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
